Anixa Biosciences (NASDAQ:ANIX) Rating Increased to Hold at Wall Street Zen

Anixa Biosciences (NASDAQ:ANIX) was upgraded by equities researchers at Wall Street Zen from a “sell” rating to a “hold” rating in a research note issued to investors on Saturday.

A number of other research firms also recently issued reports on ANIX. HC Wainwright reiterated a “buy” rating on shares of Anixa Biosciences in a research note on Friday, June 12th. Citigroup reissued a “buy” rating on shares of Anixa Biosciences in a research note on Friday, June 12th. Weiss Ratings restated a “sell (e+)” rating on shares of Anixa Biosciences in a report on Wednesday. Finally, D. Boral Capital reaffirmed a “buy” rating and set a $10.00 target price on shares of Anixa Biosciences in a research report on Wednesday, April 8th. Three research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, Anixa Biosciences presently has a consensus rating of “Hold” and a consensus price target of $8.50.

Anixa Biosciences Price Performance

NASDAQ:ANIX opened at $2.91 on Friday. Anixa Biosciences has a 1-year low of $2.32 and a 1-year high of $5.46. The company has a 50-day moving average of $2.79 and a 200 day moving average of $3.04. The firm has a market cap of $99.00 million, a PE ratio of -9.39 and a beta of 0.59.

Anixa Biosciences (NASDAQ:ANIX) last posted its earnings results on Wednesday, June 10th. The company reported ($0.07) EPS for the quarter, beating analysts’ consensus estimates of ($0.10) by $0.03. Sell-side analysts anticipate that Anixa Biosciences will post -0.31 EPS for the current fiscal year.

Insider Buying and Selling

In other news, CEO Amit Kumar purchased 21,000 shares of the firm’s stock in a transaction on Friday, June 12th. The stock was acquired at an average cost of $2.50 per share, with a total value of $52,500.00. Following the completion of the transaction, the chief executive officer owned 630,812 shares in the company, valued at $1,577,030. This represents a 3.44% increase in their position. The purchase was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Corporate insiders own 26.40% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of the company. 683 Capital Management LLC bought a new position in shares of Anixa Biosciences during the 4th quarter worth approximately $355,000. ExodusPoint Capital Management LP acquired a new stake in Anixa Biosciences in the fourth quarter valued at approximately $293,000. Susquehanna International Group LLP boosted its stake in Anixa Biosciences by 378.4% in the third quarter. Susquehanna International Group LLP now owns 80,387 shares of the company’s stock valued at $265,000 after acquiring an additional 63,584 shares in the last quarter. Virtu Financial LLC purchased a new position in Anixa Biosciences in the fourth quarter worth $161,000. Finally, State Street Corp grew its holdings in Anixa Biosciences by 32.0% in the fourth quarter. State Street Corp now owns 159,040 shares of the company’s stock worth $496,000 after purchasing an additional 38,540 shares during the last quarter. Hedge funds and other institutional investors own 29.13% of the company’s stock.

Anixa Biosciences Company Profile

Anixa Biosciences is a clinical-stage immuno-oncology and infectious disease company developing novel cell-based immunotherapies and vaccine platforms. Through its Anixa Therapeutics division, the company is advancing antibody and T-cell modalities, including an ovarian cancer immunotherapy candidate and a COVID-19 vaccine leveraging a proprietary virus-like particle (VLP) technology. Its research pipeline emphasizes modular vaccine design and personalized cancer cell therapy aimed at inducing durable immune responses against solid tumors.

In parallel, Anixa Diagnostics is developing the ADAPT diagnostic platform, a high-throughput proteomics approach using engineered peptides derived from spider venom.